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Abstract
Background: Dengue hemorrhagic fever (DHF) is the severe and life-threatening syndrome that can develop after infection
with any one of the four dengue virus (DENV) serotypes. DHF occurs almost exclusively in individuals with secondary
heterologous DENV infections and infants with primary DENV infections born to dengue immune mothers. The widely
accepted explanation for the pathogenesis of DHF in these settings, particularly during infancy, is antibody-dependent
enhancement (ADE) of DENV infection.
Methods and Findings: We conducted a prospective nested case-control study of DENV infections during infancy. Clinical
data and blood samples were collected from 4,441 mothers and infants in up to two pre-illness study visits, and surveillance
was performed for symptomatic and inapparent DENV infections. Pre-illness plasma samples were used to measure the
associations between maternally derived anti-DENV3 antibody-neutralizing and -enhancing capacities at the time of DENV3
infection and development of infant DHF. The study captured 60 infants with DENV infections across a wide spectrum of
disease severity. DENV3 was the predominant serotype among the infants with symptomatic (35/40) and inapparent (15/20)
DENV infections, and 59/60 infants had a primary DENV infection. The estimated in vitro anti-DENV3 neutralizing capacity at
birth positively correlated with the age of symptomatic primary DENV3 illness in infants. At the time of symptomatic DENV3
infection, essentially all infants had low anti-DENV3 neutralizing activity (50% plaque reduction neutralizing titers [PRNT50]
#50) and measurable DENV3 ADE activity. The infants who developed DHF did not have significantly higher frequencies or
levels of DENV3 ADE activity compared to symptomatic infants without DHF. A higher weight-for-age in the first 3 mo of life
and at illness presentation was associated with a greater risk for DHF from a primary DENV infection during infancy.
Conclusions: This prospective nested case-control study of primarily DENV3 infections during infancy has shown that
infants exhibit a full range of disease severity after primary DENV infections. The results support an initial in vivo protective
role for maternally derived antibody, and suggest that a DENV3 PRNT50.50 is associated with protection from symptomatic
DENV3 illness. We did not find a significant association between DENV3 ADE activity at illness onset and the development of
DHF compared with less severe symptomatic illness. The results of this study should encourage rethinking or refinement of
the current ADE pathogenesis model for infant DHF and stimulate new directions of research into mechanisms responsible
for the development of DHF during infancy.
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Introduction
Dengue hemorrhagic fever (DHF) is the most severe and
sometimes fatal form of illness after infection with any one of the
four dengue virus (DENV) serotypes [1]. The global spread of
dengue, and the incidence of epidemic DHF, have increased
dramatically over the past 50 y and continue on an upward
trajectory [2,3]. An accurate understanding of DHF pathogenesis is
important for clinicians, public health officials, and vaccine
researchers in dengue affected countries. DHF occurs almost
exclusively in two clinical settings: children and adults with
secondary heterologous DENV infections and infants with primary
DENV infections born to dengue-immune mothers [3]. The most
widely accepted and repeatedly cited explanation for the patho-
genesis of DHF in these settings is antibody-dependent enhance-
ment (ADE) of DENV infection [4–6]. The ability of subneutraliz-
ing virus-specific antibodies to enhance DENV as well as other
flavivirus infections in vitro was first recognized in the 1960s [7] and
has been extensively studied [8–11]. The ADE model for DHF
proposes that anti-DENV IgG, actively acquired from a previous
heterologous DENV infection, or passively acquired in infants from
maternal-fetal transfer, enhances DENV infection of Fc receptor-
bearing cells under particular conditions in vivo. The ADE of
DENV infection increases viral load (infected cell mass) and triggers
a host immunological cascade that leads to DHF [3,12].
The lynchpin of the ADE disease model lies in its explanation of
DHF in infants, where maternally derived anti-DENV IgG levels
decay over time [13] in the absence of virus-specific memory B- and
T cells. The argument for a pathogenic and central role of ADE in
infant DHF has been largely based on linking two epidemiological
associations. In dengue endemic regions, the age-related prevalence
of infant primary DHF peaks around 6–8 mo of age and then drops
off to low levels [12,14,15]. In blood samples collected from infant
cohorts in dengue endemic regions, this age range generally
coincides with peak in vitro ADE activity [12,14,16]. We are
conducting a prospective clinical study in the Philippines of DENV
infections during infancy. We have performed a nested case-control
study of infant DENV infections during the 2007 season to directly
measure the associations between maternally derived anti-DENV
IgG-neutralizing and -enhancing capacities at the time of infection
and development of DHF. This report is the first to directly test
predictions of the ADE model for infant DHF by using pre-illness
plasma samples collected from infants with primary DENV
infections and a wide spectrum of clinical disease severity. The
results provide important new information regarding infant dengue
and the development of DHF.
Methods
Ethics Statement
The study protocol was approved by the institutional review
boards of the Research Institute for Tropical Medicine, Philip-
pines, and the University of Massachusetts Medical School.
Mothers and their healthy infants were recruited and enrolled
after providing written informed consent. The clinical study is
registered at www.clinicaltrials.gov (identifier NCT00377754), and
the study protocol is provided as supporting information (Text S1).
Study Design
Study enrollment began in October 2006, and surveillance for
acute febrile illnesses began in January 2007, in San Pablo,
Laguna, Philippines. This paper describes cases identified between
January 2007 and January 2008 and is the first report from the
ongoing clinical study.
Blood samples were collected from the infant and mother at the
first study visit when the infant was approximately 6–18 wk old. A
second serial blood sample was collected from infants at their next
study visit between ages 4–7 mo. A third serial blood sample was
collected in November/December 2007 from a subset of 250
infants without any reported febrile illnesses (Figure 1). Clinical
and epidemiological information were also collected at each study
visit. Normalized child growth indicators were determined using
World Health Organization (WHO) child growth standards [17].
We conducted surveillance year round for hospitalized acute
febrile illnesses in study infants across the seven hospitals serving
San Pablo. During the rainy season (June–November 2007),
mothers were encouraged to bring their infants to the San Pablo
City Health Office for evaluation of outpatient febrile illnesses.
Acute- and convalescent-phase (day 14) blood samples were
obtained from study infants with febrile illnesses that did not have
an obvious source at time of presentation (e.g., lobar pneumonia,
bacterial meningitis, pyelonephritis). Routine clinical information
was abstracted daily during any hospitalization and at the acute
and convalescent time points for all febrile study infants.
Identification and Characterization of DENV Infections
A DENV infection was identified in febrile infants by serotype-
specific reverse-transcription (RT)-PCR in acute-phase sera [18]
and DENV IgM/IgG ELISA [19] in paired acute and convalescent
phase sera. Primary or secondary DENV infections were identified
by previously established serologic criteria for the paired IgM/IgG
ELISA results [19]. The infecting DENV serotype was identified by
RT-PCR for all the symptomatic infants except one. A sample for
RT-PCR was not collected for this infant, but a monotypic rise in
anti-DENV3 neutralizing antibody titers was seen in the paired
acute and convalescent phase sera. Viremia levels in acute-phase
sera from DENV3-infected infants were quantified using a validated
qRT-PCR assay [20].
Serial blood samples (study visits 1, 2, and 3) from a subset of
250 infants without reported febrile illnesses were screened for
evidence of clinically inapparent DENV infection using a
hemagglutination-inhibition (HAI) assay to DENV1-4 and Japa-
nese encephalitis virus (JEV) [21]. Infants with DENV/JEV HAI
titers #40 and ,4-fold changes across study visits 1, 2, and 3 were
identified as DENV-uninfected during the surveillance period
(nondengue controls). Infants with a $4-fold rise in DENV HAI
titers between two time points were then tested by plaque
reduction neutralizing antibody assay to DENV1-4 and JEV, as
described below. A primary DENV infection was identified by a
.4-fold rise in DENV 50% plaque reduction neutralization titers
(PRNT50) between two time points with a monotypic pattern [22].
The DENV serotype with the highest PRNT50 in a monotypic
pattern was assumed to be the serotype that produced the
clinically inapparent infection.
Laboratory and radiographic investigations for hospitalized
infants with DENV infections were directed by the treating
physicians. There were $3 serial determinations of hematocrit
and platelets performed for all the hospitalized infants and covering
the period of defervescence. Hemoconcentration was measured by
comparing the maximum recorded hematocrit (around the time of
defervescence and platelet nadir) with the minimum recorded
hematocrit at either the beginning or end of hospitalization. None of
the infants received red blood cell or whole blood transfusions.
Hospitalized infants with DENV infection were classified as having
DHF only when review of their clinical course and all clinical data
strictly met the WHO classification criteria [23]. All the
nonhospitalized infants with DENV infections had mild self-
resolving febrile illnesses ,1 wk in duration.
Prospective Study of Infant Dengue
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Antibody-Mediated Neutralization and Enhancement
Assays
Plaque reduction neutralizing antibody assays against DENV3
strain 16562 were performed on serial dilutions of heat-inactivated
(56uC630 min) maternal and pre-illness plasma samples, as
previously described [22]. DENV3 PRNT50 were determined
using a sigmoid dose-response (variable slope) curve fit and
reported as reciprocal values. The maternal plasma PRNT50 was
used to estimate the PRNT50 at birth in the infant. Only one
mother had evidence of a DENV infection between infant birth
and the first study visit and was excluded from data analysis. The
mother did not report a febrile illness between birth and the first
study visit when her infant was 63 d old. However, concurrent
maternal and infant DENV3 PRNT50 at the first study visit were
10,762 and 20, respectively.
ADE experiments were performed with FccIIa receptor-bearing
K562 cells [10] under previously optimized conditions. In brief, the
most proximal pre-illness plasma sample from each infant was heat
inactivated (56uC630 min) and diluted to achieve the neutralizing
capacity at time of infection. This plasma dilution was pre-
incubated with DENV3 strain 16562 for 1 h at 37uC and then
added to 2.56105 K562 cells at a multiplicity of infection= 0.015.
Cell culture supernatants were collected at 72 h and DENV3 levels
measured by qRT-PCR assay (values expressed as DENV3 genome
equivalents [eqs]/ml) [20]. Three independent ADE experiments
were performed. Negative controls were DENV3 infection alone
and DENV3 pre-incubated with flavivirus seronegative plasma.
The positive control was DENV3 pre-incubated with a dilution of
DENV3-immune infant plasma.
Statistical Analysis
SPSS (version 12.0) and STATA (version 9.0) software were
used for the statistical analyses. SigmaPlot (version 9.0) was used to
fit plaque reduction neutralization data to sigmoid dose-response
(variable slope) curves [11] and determine the PRNT50.
Parametric tests (Student’s t-test, ANOVA, Pearson correlation)
were used for comparisons and correlations among normally
distributed variables. Wilcoxon ranked-sum and Kruskal-Wallis
tests were used for comparisons of variables that were not normally
distributed. Spearman’s rank correlation was used for correlations
between variables not normally distributed. Pearson x2 test was
used for comparisons of categorical variables among disease
severity groups. A mixed-effects least-squares regression model
with compound symmetry was used for comparisons of the ADE
experimental data with three repeated measures (p-values were
obtained from the model). Mean or median values are presented
with their respective 95% confidence intervals (CIs). p,0.05 was
considered significant; 0.05# p-values ,0.10 were considered a
nonsignificant trend.
Results
Study Participants and Characteristics
4,441 infants and their mothers participated in the prospective
study of DENV infections during the time period covered in this
report (Figure 1). Surveillance between January 2007 and January
2008 captured 97 hospitalized and 256 nonhospitalized infants with
acute febrile illnesses that did not have an obvious source at the time of
presentation. 40/353 (11%) of these acute febrile illnesses were caused
by DENV infections. In a subset of 250 infants without reported
febrile illnesses through November/December 2007, we identified an
additional 20 infants (8%) who had a clinically inapparent DENV
infection. The characteristics of the DENV-infected infants are shown
in Table 1. DENV3 was the predominant serotype among the infants
with symptomatic (35/40) and inapparent (15/20) DENV infections
in the 2007 season. 59/60 infants had a primary DENV infection, and
subsequent analyses excluded the one infant with a secondary
DENV3 infection. There was a 1:1 ratio of hospitalized:nonhospita-
Figure 1. Flowchart of study participation, October 2006–January 2008. The ages at each study visit are presented as the median (range) in
months. *, A subset of 250 infants who had completed study visits 1 and 2 were selected for a third study visit in November/December 2007. These
infants did not have any previously reported febrile illnesses.
doi:10.1371/journal.pmed.1000171.g001
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lized illnesses among infants with symptomatic primary dengue. 9/20
(45%) of the infants with hospitalized primary dengue had
unambiguous DHF. Five of these infants had DHF grades III/IV
(dengue shock syndrome [DSS]), including one infant who died. The
remaining four infants were classified as DHF grade I with
hemoconcentration ranging from 27%–44% (one DHF grade I infant
also had a large pleural effusion on a chest radiograph). None of the
DENV-infected infants had clinically significant bleeding.
All the infants included in the nested case-control analysis were
born at full-term by maternal history. The median age at study
enrollment was 2.4 mo (Table 1). The peak number of
symptomatic primary DENV infections was seen between ages
4–8 mo (Figure 2). There was a nonsignificant trend towards a
younger age at time of illness in the infants with DHF compared to
symptomatic dengue without DHF (median age at illness onset 5.7
versus 7.9 mo, DHF versus not DHF, p=0.09). The DHF infants
Table 1. Study subject characteristics.
Study Subject Characteristics Symptomatic DENV Infectiona (n=40)
Inapparent DENV
Infectiona (n=20)
Comparisons
(p-values)
Hospitalized (n=21) Not Hospitalized (n=19)
DHF (n=9) Not DHF (n=12) Not DHF (n=19)
DENV serotype DENV3 (n= 9) DENV3 (n= 12) DENV1 (n= 1); DENV2 (n= 4);
DENV3 (n= 14)
DENV2 (n= 5); DENV3
(n=15)
—
1u versus 2u DENV infection 1u2n= 9 1u2n= 11; 2u2n= 1 1u2n=19 1u2n= 20 —
Gender ratio (male:female)b 6:3 7:4 11:8 10:10 p= 0.9
Age at onset of dengue illness
(mo)b (median, 95% CI)
5.7 (4.3–6.9) c c — p= 0.09 (DHF versus
symptomatic, not DHF)
Age at study enrollment (mo)b
(median, 95% CI)
2.5 (1.6–3.5) d d 2.3 (2.0–2.4) p= 0.9
aInfants with symptomatic and inapparent DENV infections were identified as described in Methods.
bInfant with secondary DENV infection excluded (primary DENV infections only).
c 7.9 (6.5-9.3) for these two categories combined.
d2.4 (1.8-4.6) for these two categories combined.
doi:10.1371/journal.pmed.1000171.t001
Figure 2. Age distribution of infants with symptomatic primary DENV infections. Filled bars, hospitalized infants with DHF. Open bars,
hospitalized and nonhospitalized infants without DHF.
doi:10.1371/journal.pmed.1000171.g002
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had higher weight-for-age z-scores [17] on illness presentation
compared to the symptomatic infants without DHF (p=0.04). A
higher weight-for-age z-score at study enrollment was also
associated with subsequent development of DHF compared to
all other DENV-infected infants (p=0.03) (Figure 3). Length-for-
age z-scores also trended higher in the DHF infants at study
enrollment (p=0.07), but were not measured at illness presenta-
tion. Weight-for-length z-scores were not different between DHF
versus not DHF infants at study enrollment (p=0.4).
Antibody-Mediated Neutralizing Capacity at the Time of
Primary DENV3 Infection
In order to examine the potential role of maternally derived
anti-DENV IgG in shaping disease severity, we estimated the
DENV3 PRNT50 at time of infection in the 34 infants with
symptomatic primary DENV3 infections. We calculated individual
first-order decay rates of maternally derived DENV3 PRNT50 in
these 34 infants using two infant pre-illness plasma samples
(n=17), or one maternal and one infant pre-illness plasma sample
(n=14) (median decay rate was used in n=3 infants). Endpoint
DENV3 PRNT50 at the time of infection were then extrapolated.
In these infants and DENV-uninfected controls (n=30), the mean
half-life (t1/2) of DENV3 PRNT50 was 38 d (95% CI 34–42 d),
and was not significantly different if calculated using two infant
plasma samples or one maternal and one infant plasma sample
(p=0.3).
A protective role for maternally derived anti-DENV3 IgG was
suggested by a strong positive correlation between the estimated
DENV3 PRNT50 at birth and the infant age at onset of
symptomatic primary DENV3 infection (Pearson r=0.64 [0.36–
0.81], p,0.001) (Figure 4A). At the time of symptomatic infection,
extrapolated DENV3 PRNT50 were #50 in all infants and the
geometric mean titer (GMT) was ,5. There were no significant
associations between the extrapolated DENV3 PRNT50 at time of
symptomatic infection and disease severity (p=0.9) (Figure 4B).
Antibody-Mediated Enhancing Capacity at the Time of
Primary DENV3 Infection
The ADE model predicts that infants who develop DHF will
have maternally derived anti-DENV IgG levels at the time of
infection that enhance DENV infection to a greater degree than
infants without DHF. We diluted the most proximal pre-illness
plasma sample from the 34 infants with symptomatic primary
DENV3 infection to achieve their estimated DENV3 PRNT50 at
illness onset and measured the concomitant ADE activity. In
nearly all cases, pre-incubation of DENV3 with the plasma
dilutions increased viral production from K562 cells compared
with virus alone or flavivirus seronegative plasma. The plasma
dilutions from 9/9 infants with DHF and 22/25 infants without
DHF were able to increase DENV3 production .0.5 log10
genome eqs/ml above virus infection alone (p=0.6). There were
no significant associations between measures of disease severity
and antibody-mediated DENV3 enhancing capacity at the time of
infection (DHF versus not DHF, p=0.13; DHF versus not
hospitalized, not DHF, p=0.19; hospitalized versus not hospital-
ized, p=0.5) (Figure 5). The ADE pathogenesis model also
predicts that enhancing capacity at the time of DENV infection
should positively correlate with viral load. We measured viremia
levels by qRT-PCR in single acute illness plasma samples from
33/34 infants with symptomatic primary DENV3 infections. As
Figure 3. World Health Organization (WHO) weight-for-age z-scores at study enrollment and acute illness in infants with primary
DENV infections. Closed circles, weight-for-age z-scores at illness presentation; open triangles, weight-for-age z-scores at study enrollment. Values
are presented as the mean with 95% CIs. *, p= 0.04, weight-for-age z-scores at presentation in DHF infants versus symptomatic dengue, not DHF,
infants. {, p=0.03, weight-for-age z-scores at study enrollment in DHF infants versus symptomatic and inapparent dengue, not DHF, infants.
doi:10.1371/journal.pmed.1000171.g003
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expected, the viremia levels were inversely correlated with the day
of illness (Spearman’s r=20.62, p,0.001). We used viremia levels
obtained within 3 d after illness onset as the best available estimate
of peak viremia [24,25]. These early viremia levels ranged from
2.9–9.1 log10 DENV3 genome eqs/ml (Figure 6A). During this
time period, there was a nonsignificant trend towards higher mean
viremia levels in infants with DHF compared to those without
DHF (DHF versus not DHF, 8.060.5 versus 6.962.2 log10
DENV3 genome eqs/ml [mean 6 standard deviation], p=0.07).
Regardless of disease severity classification, the DENV3 enhancing
capacity at time of infection did not correlate with the early
viremia levels (Pearson r=0.28 [20.18, 0.63], p=0.2) (mean
regression slope [95% CI], 0.07 [20.05 to 0.19] (Figure 6B).
Discussion
This prospective study has captured the entire spectrum of
clinical disease severity among infants with primary DENV
infections—ranging from inapparent infections, mild outpatient
febrile illnesses, hospitalized illnesses without evidence of DHF,
and unambiguous hospitalized DHF/DSS. DENV3 was the
predominant infecting serotype in the 2007 dengue season covered
by this report. We therefore focused on the potential role of
maternally derived anti-DENV IgG in shaping DENV3 disease
severity. Our data support an initial in vivo protective role for high
levels of maternally derived anti-DENV3 IgG at birth. The
estimated in vitro anti-DENV3 neutralizing capacity at birth
(maternal DENV3 PRNT50 geometric mean titer [GMT]= 413,
range 41–5,690) positively correlated with the infant age of
symptomatic primary DENV3 illness (all disease severity groups).
A similar correlation was previously reported for estimated anti-
DENV2 neutralizing capacity at birth in 13 DHF infants with
primary DENV2 infections [16]. A more recent study did not
report a correlation between estimated serotype-specific neutral-
izing capacity at birth and the infant age at dengue illness [26].
However, this study combined serotype-specific PRNT50 values
for infants with DENV1-3 infections in their analysis and
performed a different in vitro neutralization assay.
All the infants in our study with symptomatic DENV3 infections
had a DENV3 PRNT50 #50 at the time of infection, and there
were no correlations between the neutralizing capacity at time of
infection and DENV3 disease severity. These data support that
primary DENV3 febrile illnesses occurred in infants when
maternally derived anti-DENV3 IgG were below effective in vivo
neutralizing concentrations. Identifying levels of neutralizing
antibody associated with clinical protection is an important issue
for dengue vaccine development and testing, as such correlates of
protective immunity have not been previously well defined. The
estimated neutralizing antibody titers at the time of primary
DENV infection in infants represent a natural study of passive
immunization. For DENV3 infections, our results suggest that a
DENV3 PRNT50 .50 is likely to correlate with clinical protection
but a measurable DENV3 PRNT50 $10 and #50 is not. These
findings are remarkably consistent with an earlier study we
conducted in older children with secondary DENV3 infections
[22]. Using the same DENV3 strain in the neutralization assays,
Figure 4. Estimated DENV3 neutralizing capacities at birth and illness onset in infants with symptomatic primary DENV3 infections.
(A) Log10 transformed PRNT50 to DENV3 in maternal plasma (estimate for birth time point) were positively correlated with infant age at onset of
symptomatic primary DENV3 infection (n= 30). Mean (95% CI) of the Pearson correlation coefficient (r) is shown. The linear regression curve and 95%
CI are shown as a solid line and dashed lines, respectively. (B) Endpoint DENV3 PRNT50 at the time of symptomatic primary DENV3 infection were
extrapolated from pre-illness plasma samples as described in the Results (n=34). Closed squares, hospitalized infants with DHF; open triangles,
hospitalized infants without DHF; open circles, nonhospitalized infants without DHF. The closed circles and error bars are the DENV3 PRNT50
geometric mean titers (GMT) and 95% CI, respectively. There were no significant differences among the disease severity groups (p= 0.9).
doi:10.1371/journal.pmed.1000171.g004
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we reported that only a pre-illness DENV3 PRNT50$100 was
associated with lower viremia and milder DENV3 disease severity.
We anticipate that similar neutralizing antibody data for other
DENV serotypes will emerge as our infant clinical study continues.
The current ADE model predicts that infant DHF develops
when subneutralizing maternally derived anti-DENV IgG en-
hances DENV infection in Fc receptor-bearing cells to higher
levels than in infants with subneutralizing anti-DENV IgG levels
who do not develop DHF [12]. We found that essentially all
infants with symptomatic DENV3 infections had subneutralizing
plasma IgG levels and measurable Fc receptor-dependent DENV3
ADE activity at the time of infection. The infants who developed
DHF did not have significantly higher frequencies or levels of
DENV3 ADE activity compared to symptomatic infants without
DHF. We recognize that some hospitalized infants classified as
‘‘not DHF’’ may have met the WHO criteria for DHF with more
intensive investigations. However, there were no significant
differences in DENV3 ADE activity between the most severe
hospitalized DENV3 illnesses and mild outpatient DENV3
illnesses, or between all hospitalized and nonhospitalized infants.
Our data cannot exclude that mean ADE levels in symptomatic
infants without DHF were actually #1.0 log10 DENV3 genome
eqs/ml lower than in the DHF infants. Notably, ADE and early
viremia levels varied widely across all the symptomatic DENV3-
infected infants, even among those with mild symptomatic primary
DENV3 illnesses. DENV3 ADE activity at the time of infection
Figure 5. ADE of DENV3 infection at illness onset in infants with symptomatic primary DENV3 infections. The most proximal pre-illness
plasma sample from each infant with symptomatic primary DENV3 infection (n= 34) was diluted to achieve the estimated neutralizing capacity at
illness onset and used in the ADE assay, as described in the Methods. Values are log10 transformed DENV3 genome eqs/ml in cell culture supernatants
at 72 h, mean6standard deviation of individual plasma samples from three independent experiments. Mean DENV3 genome eqs/ml and 95% CI are
shown for each of the disease severity groups (mean [95% CI]). Closed squares, hospitalized infants with DHF; open triangles, hospitalized infants
without DHF; open circles, nonhospitalized infants without DHF. ap,0.01 compared to virus alone; bp,0.01 compared to flavivirus seronegative
plasma control. There were no significant differences among the disease severity groups (see Results).
doi:10.1371/journal.pmed.1000171.g005
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and early viremia levels were also not correlated, although a
significant positive association with a regression slope ,0.2 may
have been missed. Our prospective study is the first to directly
examine ADE activity at the time of infection among infants
exhibiting a wide spectrum of dengue disease severity. The results
suggest that measurable ADE activity is common and varied
across all symptomatic DENV3-infected infants, and no significant
associations with DHF have yet emerged. There has been only one
previous study that examined and reported a direct association
between ADE activity and infants with primary DHF [16]. The
authors reported that peak DENV2 ADE activity in 5/13 diluted
sera from mothers of infants with primary DENV2 DHF were
above a cutoff value compared to 2/22 sera from mothers of
infants with nondengue febrile illnesses and toddlers with
secondary DHF. The dilution of maternal sera that produced
peak ADE activity was not directly linked to the time of DENV2
infection in the DHF infants. The reported data were from a single
experiment, and there was no comparison to primary DENV2-
infected infants without DHF.
We measured Fc receptor-dependent ADE of DENV3 infection
using the K562 human cell line and a highly reproducible DENV3
qRT-PCR assay. Experimental conditions for ADE assays have
not been standardized and have been previously debated [27].
The K562 cell line has been used by others to reliably measure
ADE of DENV infection in vitro [10,28,29] and support the
temporal association between ADE activity and infant DHF [14].
DENV qRT-PCR is a sensitive, accurate, and reproducible
method to measure viral production, and has always correlated
with plaque-forming virus titers or percentage of infected cells in
ADE assays [10,30]. The ADE results and conclusions in this
report are restricted to the DENV3 serotype, though the ADE
model has been proposed as a general mechanism for all infant
DHF. Future data from the ongoing clinical study should help to
determine whether the current lack of a positive correlation
between ADE activity and symptomatic dengue disease severity
will hold up within narrower confidence intervals, and also extend
our findings beyond primary infant DENV3 infections.
There is the possibility that ADE of DENV infection is
important in the pathogenesis of all symptomatic primary infant
dengue (including mild, outpatient febrile illnesses) compared to
inapparent/asymptomatic dengue. In Figure 4A, the observed
infant ages may be clustered in a window period after maternally
derived anti-DENV3 IgG drop below effective in vivo neutralizing
concentrations. If inapparent DENV3 infections are not similarly
Figure 6. Early viremia levels and ADE activity at illness onset in infants with symptomatic primary DENV3 infections. (A) Early
viremia levels in acute-phase sera from infants with symptomatic primary DENV3 infections. Values are log10 transformed DENV3 genome eqs/ml
measured in single acute-phase serum samples collected between 1–3 d after illness onset. Closed squares, hospitalized infants with DHF; open
triangles, hospitalized infants without DHF; open circles, nonhospitalized infants without DHF. Line represents the lower limit of quantitation (2.93
log10 DENV3 genome eqs/ml). (B) Mean log10 transformed DENV3 genome eqs/ml from ADE assay cell culture supernatants versus viremia levels in
single acute-phase serum samples collected between 1–3 d after illness onset (n= 21). Mean [95% CI] of the Pearson correlation coefficient (r) is
shown. The linear regression curve and 95% CI are shown as a solid line and dashed lines, respectively.
doi:10.1371/journal.pmed.1000171.g006
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clustered (i.e., shifted to the right of the symptomatic DENV3
infections), then it would suggest that an antibody-mediated effect
is associated with symptomatic DENV3 illness. We could not
pinpoint the time of inapparent DENV3 infections and therefore
could not include this group in Figure 4A or assess their relevant
ADE activity. Additional studies that can accurately capture the
ages of inapparent infant DENV infections will be important in
this regard.
Interestingly, we found that a higher weight-for-age z-score in
the first few months of life was a risk factor for developing DHF
from a subsequent primary DENV infection during infancy. This
association persisted at the time of illness presentation among
infants with symptomatic primary DENV infections. Some earlier
studies have suggested that infants with DHF are less likely to be
malnourished at presentation compared to healthy or nondengue
illness controls [31,32]. A younger infant age at the time of a
primary DENV infection has also been previously reported as a
risk factor for DHF [12]. Our study demonstrated this trend but
notably it was independent of ADE activity. The anthropometric
and age-related observations in this study should stimulate
investigations into novel potential host mechanisms involved in
the pathogenesis of infant DHF. These observations should also
alert clinicians caring for infants in dengue-endemic countries. A
high index of suspicion and close monitoring for DHF should take
place particularly for febrile infants#8 mo old with above average
WHO weight-for-age z-scores for their population.
In summary, our prospective nested case-control study found
that DENV-infected infants exhibited a wide range of disease
severity. We identified levels of maternally derived neutralizing
antibody associated with clinical protection against symptomatic
DENV3 illness. Measurable ADE activity at illness onset and early
viremia levels varied widely across all symptomatic DENV3-
infected infants, including those with mild outpatient illnesses. The
results should encourage rethinking or refinement of the currently
promulgated ADE model for infant DHF, promote prospective
studies of infant dengue, and stimulate new directions of research
into novel potential mechanisms for infant DHF.
Supporting Information
Text S1 Protocol.
Found at: doi:10.1371/journal.pmed.1000171.s001 (0.15 MB
DOC)
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Editors’ Summary
Background. Every year, dengue infects 50–100 million
people living in tropical and subtropical areas. The four
closely related viruses that cause dengue (DENV1–4) are
transmitted to people through the bites of female Aedes
aegypti mosquitoes, which acquire the viruses by feeding on
the blood of an infected person. Many people who become
infected with DENV have no symptoms but some develop
dengue fever, a severe, flu-like illness that lasts a few days.
Other people—about half a million a year—develop a
potentially fatal condition called dengue hemorrhagic fever
(DHF). In DHF, which can be caused by any of the DENVs,
small blood vessels become leaky and friable. This leakiness
causes nose and gum bleeds, bruising and, in the worst
cases, failure of the circulatory system and death. There is no
vaccine to prevent dengue and no specific treatment for
dengue fever or DHF. However, with standard medical
care—in particular, replacement of lost fluids—most people
can survive DHF.
Why Was This Study Done? DHF is increasingly common,
but why do only some people develop DHF after infection
with DENV? The widely accepted explanation for the
development of DHF is ‘‘antibody-dependent
enhancement’’ (ADE) of DENV infection. DHF occurs almost
exclusively in two settings; (i) children and adults who
become infected with a second DENV serotype after an initial
‘‘primary’’ DENV infection with a different serotype, and (ii)
infants with primary DENV infections whose mothers have
some DENV immunity. The ADE model suggests that in
individuals who develop DHF, although there are some
antibodies (proteins made by the immune system to fight
infections) against DENV in their blood (in secondary
heterologous infections, antibodies left over from the
primary infection; in infants with primary infections,
antibodies acquired from their mothers before birth), these
antibodies cannot ‘‘neutralize’’ the virus. Instead, they bind
to it and enhance its uptake by certain immune system cells,
thus increasing viral infectivity and triggering an
immunological cascade that results in DHF. In this
prospective, nested case-control study, the researchers
directly test the ADE model for infant DHF. In a
prospective study, a group of people is selected and
followed to see if they develop a disease; in a nested case-
control study, each case is compared with people in the
group who do not develop the disease.
What Did the Researchers Do and Find? The researchers
collected clinical data and blood samples from 4,441
mothers and their babies at up to two pre-illness study
visits. They then followed the infants for a year to see which
of them developed symptomatic and symptom-free DENV
infections. Finally, they used the pre-illness blood samples to
estimate the maternally derived anti-DENV antibody-
neutralizing and -enhancing capacities in the infants at the
time of DENV infection. 60 infants were infected with
DENV—mainly DENV3—during the study. All but one
infection was a primary infection. The infected infants
showed a wide range of disease severity. Infants who had
a high DENV3 neutralizing capacity at birth tended to
develop symptomatic DENV3 infections later than infants
who had a low DENV3 neutralizing capacity at birth. All the
infants who developed a symptomatic DENV3 infection had
a low estimated DENV3 neutralizing activity at the time of
infection, and nearly all had measurable levels of DENV3 ADE
activity. Infants who developed DHF did not have
significantly higher frequencies or levels of DENV3 ADE
activity than DENV3-infected infants with less severe
symptoms.
What Do These Findings Mean? These findings indicate
that maternally derived anti-DENV3 antibody initially
provides protection against dengue infections. That is,
babies born to DENV immune mothers are protected
against dengue infections by maternally derived
antibodies. Over time, the level of these antibodies
declines until eventually the infant becomes susceptible to
DENV infections. However, the lack of a significant
association between the estimated level of DENV3 ADE
activity at illness onset and the development of DHF rather
than a less severe illness throws doubt onto (but does not
completely rule out) the current ADE pathogenesis model for
infant DHF, at least for DENV3 infections. The results of this
study, the researchers conclude, should encourage
rethinking or refinement of the ADE model for infant DHF
and should promote further prospective studies into the
development of DHF during infancy.
Additional Information. Please access these Web sites via
the online version of this summary at http://dx.doi.org/10.
1371/journal.pmed.1000171.
N TropIKA.net provides review articles, news, opinions,
research articles, and reports on dengue (in English)
N The US Centers for Disease Control and Prevention provide
detailed information about dengue fever and dengue
hemorrhagic fever (in English and Spanish)
N The World Health Organization provides information on
dengue fever and dengue hemorrhagic fever around the
world (in several languages)
N Links to additional resources about dengue are provided
by MedlinePlus (in English and Spanish)
N Wikipedia has a page on antibody-dependent enhance-
ment of viral infections (note that Wikipedia is a free online
encyclopedia that anyone can edit; available in several
languages)
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